Developing a drug to enhance stem cell growth for faster recovery after chemotherapy and bone marrow transplant
Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant
This study is testing a new drug that helps boost the growth of stem cells in patients getting a stem cell transplant, with the goal of speeding up recovery and reducing the risk of infections after the procedure.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ship of Theseus, LLC NIH-funded |
| Lab location | 1 site (Eagleville, UNITED STATES) |
| Project ID | NIH-10918070 on NIH RePORTER |
What this research studies
This research focuses on improving the recovery process for patients undergoing hematopoietic stem cell transplants (HSCTs) by using a novel drug that enhances the growth of stem cells in the body. The drug, a modified version of a nuclear transcription factor, is designed to be administered briefly before the transplant, allowing for better expansion of donor stem cells without causing them to differentiate. This approach aims to reduce the duration of neutropenia, a condition that leaves patients vulnerable to infections after their bone marrow is removed and before the transplant takes effect. By shortening the time patients spend neutropenic, the research seeks to improve patient outcomes and reduce hospital costs associated with HSCTs.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with certain blood cancers who are scheduled to undergo hematopoietic stem cell transplants.
Not a fit: Patients who are not undergoing HSCTs or those with conditions unrelated to blood cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster recovery times and reduced infection risks for patients undergoing stem cell transplants.
How similar studies have performed: While the approach of using a drug to enhance stem cell expansion is innovative, similar strategies have shown promise in preliminary trials, indicating potential for success.
Where this research is happening
Eagleville, UNITED STATES
- Ship of Theseus, LLC — Eagleville, United States (Active)
Researchers
- Principal investigator: Elser, Jeremy a — Ship of Theseus, LLC
- Study coordinator: Elser, Jeremy a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.